Fate Therapeutics, Inc. - FATE STOCK NEWS

Fate Therapeutics reported promising interim Phase 1 results for FT516, an off-the-shelf NK cell therapy for relapsed/refractory B-cell lymphoma, at the ASCO Annual Meeting. Out of 11 patients, 8 achieved an objective response, including 6 complete responses, with no serious adverse events or grade 3+ side effects noted. The ongoing study is currently enrolling in its fourth dose cohort. The favorable safety profile and activity signal potential for future indication-specific cohorts aimed at combining FT516 with CD20-targeted therapies.

Fate Therapeutics, a clinical-stage biopharmaceutical company, has announced its participation in two upcoming investor conferences. The Jefferies Virtual Healthcare Conference will take place on June 1, 2021, at 1:00 p.m. ET, followed by the BofA Securities 2021 Napa Biopharma Virtual Conference on June 15, 2021, at 5:30 p.m. ET. Investors can access live webcasts on the company's website under the 'Events & Presentations' section. Fate Therapeutics focuses on developing innovative cellular immunotherapies using its proprietary iPSC platform.

Fate Therapeutics announced encouraging interim Phase 1 results for its off-the-shelf, iPSC-derived NK cell therapies, FT516 and FT538, in treating relapsed/refractory AML. Of 12 patients, 5 achieved complete leukemic blast clearance, with FT516 showing no dose-limiting toxicities or cytokine-related side effects. Notably, 2 patients from the second dose cohort maintained remission for over six months without further intervention. FT538 demonstrated anti-leukemic activity with one patient achieving a complete response. The studies indicate potential for durable treatments in outpatient settings.

Fate Therapeutics reported its Q1 2021 results, highlighting a strong cash position of $888.4 million following a $460 million public offering. Revenue reached $11.1 million, supported by collaborations with Janssen and Ono. The company plans to advance its FT538 program for solid tumors and will present Phase 1 data on FT516 and FT538 at an investor event on May 13. However, the PROTECT study for ProTmune did not meet its primary endpoint, leading to the discontinuation of its development.

Fate Therapeutics (NASDAQ: FATE) will host a conference call on May 5, 2021, at 5:00 p.m. ET to report its Q1 2021 financial results and provide a corporate update. Stakeholders can participate by calling toll-free at 800-708-4539 or toll at 847-619-6396, using confirmation number 50156207. The live audio webcast will be accessible on the company’s investor relations section of their website. Fate Therapeutics focuses on developing cellular immunotherapies for cancer, leveraging its proprietary iPSC product platform.

Fate Therapeutics announced that two oral and two digital presentations covering its iPSC-derived cancer immunotherapy pipeline will be featured at the 24th ASGCT Annual Meeting from May 11-14, 2021. Their FT516 and FT538 programs for treating relapsed/refractory acute myeloid leukemia (AML) will be highlighted during a virtual investor event on May 13. The ongoing clinical trials are investigating FT516 and FT538, aimed at enhancing NK cell activity against cancers, utilizing an innovative iPSC product platform.

Fate Therapeutics (NASDAQ: FATE) announces the retirement of Chief Scientific Officer Daniel D. Shoemaker, effective June 30, 2021, after 12 years with the company. Shoemaker has been instrumental in advancing the company's iPSC Product Platform. Bob Valamehr will lead research and development moving forward. Fate Therapeutics specializes in engineered cell therapies for cancer treatment, focusing on off-the-shelf iPSC-derived products. The firm holds over 350 patents and is recognized for its innovative approaches in cellular immunotherapy.

Fate Therapeutics (NASDAQ: FATE) announced its participation in two upcoming investor conferences. The Barclays Global Healthcare Conference is scheduled for March 11, 2021, from 11:30 AM to 11:55 AM ET, followed by the Oppenheimer Virtual 31st Annual Healthcare Conference on March 17, 2021, from 1:10 PM to 1:40 PM ET. Both presentations will be available via live webcast on the Company's website under 'Events & Presentations.' Fate Therapeutics focuses on cellular immunotherapies for cancer and is currently developing innovative therapies including natural killer cell and T-cell immunotherapies.

Fate Therapeutics reported promising interim data from its FT516 Phase 1 study, showing objective responses, including two complete responses in 3 of 4 patients with relapsed/refractory B-cell lymphoma. FT596 demonstrated clinical activity in refractory DLBCL with a partial response in one patient. The FDA allowed the IND application for FT576, the first cell therapy engineered with four anti-tumor modalities. As of December 31, 2020, Fate held over $482 million in cash and investments and generated $15.9 million in revenue for Q4 2020, with R&D expenses of $39 million.